Valneva Says Ixchiq Chikungunya Vaccine Response Lasts Five Years

MT Newswires Live11-10

Valneva (VALN) said Tuesday that its vaccine against chikungunya, a mosquito-borne viral disease, maintained a 94% antibody response rate five years after a single dose of Ixchiq.

The results were based on 221 healthy adults evaluated five years after vaccination and antibody levels were comparable in adults over 65 and younger groups, the company said.

The study participants will continue to be monitored for up to 10 years to assess the long-term durability of the immune response, Valneva said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment